Stahist AD Availability: What Providers and Prescribers Need to Know in 2026

Stahist AD (chlorcyclizine HCl 25 mg / pseudoephedrine HCl 60 mg) is not on the FDA's Drug Shortage list in 2026 — but that doesn't mean patients can easily fill it. Prescribers are increasingly hearing from patients who've been turned away at multiple pharmacies. This guide covers what's driving the availability gaps and how to advise your patients effectively.

Clinical Overview: Stahist AD Pharmacology

Stahist AD is a fixed-dose combination of:

Chlorcyclizine HCl (25 mg): A first-generation piperazine antihistamine with H1 receptor antagonism. Onset within 30-40 minutes; duration approximately 6-8 hours. Carries sedative and anticholinergic properties, which makes it less preferred for daytime use but potentially beneficial when sedation is desired.

Pseudoephedrine HCl (60 mg): A sympathomimetic amine acting primarily on alpha-adrenergic receptors to reduce mucosal edema. Oral pseudoephedrine remains the most clinically effective oral decongestant; oral phenylephrine was deemed ineffective by the FDA advisory committee in 2023.

FDA-approved indications include allergic rhinitis (seasonal and perennial), vasomotor rhinitis, allergic conjunctivitis, nasal congestion, and general cold and upper respiratory allergy symptoms. Dosing: 1 tablet PO q6-8h; max 3 tablets/24 hours for adults.

Why Availability Varies: The Distribution Problem

Stahist AD is manufactured exclusively by Magna Pharmaceuticals, Inc. — a small pharmaceutical company without the distribution infrastructure of major manufacturers. Several factors drive the availability inconsistency that patients report:

Limited wholesaler distribution: Magna Pharmaceuticals distributes through a smaller wholesaler network. Major pharmacy chains may not have Stahist AD in their primary formularies.

Pseudoephedrine regulatory burden: Pharmacies must track all pseudoephedrine-containing products under CMEA requirements. Some pharmacies minimize the number of pseudoephedrine SKUs they stock to reduce compliance burden, favoring high-volume brands over niche combinations.

No generic substitution option: There is no AB-rated generic equivalent for Stahist AD tablets, so pharmacists cannot automatically substitute when the brand is out of stock. Prescribers must actively write for an alternative.

Clinically Equivalent Alternatives to Consider

When Stahist AD is unavailable, the following alternatives provide comparable symptom coverage:

Chlorpheniramine maleate 4 mg / pseudoephedrine HCl 60 mg (generic, e.g., Aprodine) — closest structural match; first-generation antihistamine with pseudoephedrine; generic broadly available

Loratadine 5 mg / pseudoephedrine 120 mg (Claritin-D 12h) — appropriate for patients prioritizing non-sedating daytime coverage; OTC; widely available

Cetirizine 5 mg / pseudoephedrine 120 mg (Zyrtec-D 12h) — mild sedation; good for patients with moderate allergy burden plus congestion

Fexofenadine 60 mg / pseudoephedrine 120 mg (Allegra-D 12h) — non-sedating; best for patients requiring maximum daytime alertness; avoid grapefruit juice

Important Contraindication and Interaction Reminders

These apply to Stahist AD and all pseudoephedrine-containing alternatives:

MAOI contraindication: Pseudoephedrine is contraindicated within 14 days of MAOI use; risk of hypertensive crisis

Cardiovascular considerations: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias; pseudoephedrine elevates systolic BP

Urinary retention: Both chlorcyclizine (anticholinergic) and pseudoephedrine (alpha-agonist) can worsen urinary retention; use caution in BPH patients

Glaucoma: Anticholinergic effects of chlorcyclizine may worsen narrow-angle glaucoma; evaluate before prescribing

Thyroid disease: Pseudoephedrine should be used with caution in patients with hyperthyroidism

Advising Patients Who Can't Find Stahist AD

When counseling patients about finding Stahist AD, recommend they use medfinder — a service that calls pharmacies near the patient to check which ones can fill the prescription. This is significantly more efficient than patients calling multiple pharmacies themselves, and it's particularly useful for pseudoephedrine-containing products where online inventory lookup is unreliable.

Additionally, consider proactively writing a substitute prescription at the time of the original visit — particularly if your patient has previously had trouble filling Stahist AD — with a note authorizing pharmacist substitution with chlorpheniramine/pseudoephedrine.

Summary for Prescribers

No active FDA or ASHP shortage for Stahist AD in 2026

Limited distribution by small manufacturer (Magna Pharmaceuticals) is the root cause of access challenges

No AB-rated generic; pharmacists cannot auto-substitute

Best alternatives: chlorpheniramine/pseudoephedrine (closest match), Claritin-D, Zyrtec-D, or Allegra-D

Recommend medfinder to patients who are struggling to locate it at local pharmacies